Introduction
============

Hypertension is an important public health challenge, in which medication and blood pressure control are primary concerns.[@b1-ppa-6-499],[@b2-ppa-6-499] More importantly, hypertension is a significant risk factor in the development of cardiovascular disease and stroke, which are the leading causes of death in the US.[@b3-ppa-6-499],[@b4-ppa-6-499] Each year, over 46 million Americans visit physician offices and hospital outpatient and emergency departments with hypertension as their principal diagnosis, and subsequently produce an estimated direct and indirect cost of approximately \$50.6 billion.[@b5-ppa-6-499],[@b6-ppa-6-499] Approximately one in three Americans has hypertension, and the disease affects over 76 million people older than 20 years of age.[@b6-ppa-6-499] It is estimated that by 2030, an additional 27 million people could have hypertension, which represents a 9.9% increase in prevalence from 2010.[@b6-ppa-6-499] Although hypertension is a considerable health concern, poor control of high blood pressure is a prevailing trend in the US, with less than 48% of treated patients having adequate control (\<140 mmHg systolic and 90 mmHg diastolic).[@b1-ppa-6-499],[@b6-ppa-6-499],[@b7-ppa-6-499]

Poor adherence has been cited as the primary reason why patients do not achieve full treatment benefits.[@b8-ppa-6-499],[@b9-ppa-6-499] This concept also applies to the management of hypertension, because patients have been shown to be noncompliant or do not fully adhere to prescribed treatment regimens.[@b10-ppa-6-499] An earlier study evaluating 8643 patients started on antihypertensive therapies found that only 20% achieved good levels of adherence, defined as a ≥80% medication possession ratio based on physician's instructions for use. Twenty-one percent of these patients did not fill a second prescription within the 12-month follow-up period.[@b11-ppa-6-499] Similarly, a study evaluating adherence to antihypertensive medications prescribed upon hospital discharge showed that only 54% of patients were adherent to all of their initial medications at one year.[@b10-ppa-6-499]

The implications of nonadherence to antihypertensive medication are well documented. Studies suggest that patients who are adherent to antihypertensive medications are 45% more likely to achieve blood pressure control and are more likely to attain clinically relevant goals.[@b12-ppa-6-499],[@b13-ppa-6-499] A 25% incremental increase in medication adherence has also been associated with a 1.0 mmHg (95% confidence interval −1.5, −0.6 mmHg) and a 1.2 mmHg (95% confidence interval −1.4, −0.9 mmHg) reduction in systolic and diastolic blood pressures, respectively, thus contributing to improved antihypertensive treatment outcomes.[@b13-ppa-6-499]

Patient adherence in a community setting is associated with various factors that lead to intentional (the patient decides to not take their medication) and unintentional (the patient forgets to take their medication or is careless with the prescribed medication regimen)[@b14-ppa-6-499] behaviors. Such factors that lead to intentional behaviors are the cost of medication, presence of adverse effects, or a lack of understanding of the seriousness of the disease. The existence of one or more intentional, medication-based causal factors considerably increases the risk of patient nonadherence.[@b15-ppa-6-499] Intentional barriers have been traditionally addressed through patient assistance or disease state management programs; however, little emphasis has been placed on methods to address unintentional barriers to patient adherence.[@b16-ppa-6-499] Unintentional nonadherence barriers are often predicted by medication beliefs, chronic disease, and sociodemographics.[@b14-ppa-6-499] At present, very few interventional studies have been conducted to identify patient adherence barriers and match patients to interventions designed to affect these behavioral barriers.[@b16-ppa-6-499] According to a review of patient adherence by Morisky et al, the five most common types of nonadherence with medication are "failing to have a prescription filled", "taking an incomplete dose", "taking the medication at the wrong time", "forgetting to take one or more medications", and "stopping the medication". These nonadherence behaviors require individual consideration in order to develop personalized strategies to improve patient compliance.[@b17-ppa-6-499],[@b18-ppa-6-499]

Adherence-oriented blister packaging may improve treatment adherence and reduce compliance barriers in community and outpatient settings. However, improved packaging has not been used widely and has rarely been studied for medications used to treat chronic or long-term illnesses.[@b19-ppa-6-499] One large-scale epidemiologic analysis comparing the effect of calendar blister packaging with traditional prescription vials on long-term refill behavior found that calendar blister packaging in patients treated with angiotensin-converting enzyme inhibitors was associated with a significantly greater length of treatment and proportion of days covered, but not medication possession ratio.[@b20-ppa-6-499] Further research on medication possession ratio and adherence correlations was deemed necessary.[@b20-ppa-6-499]

In October 2009, Novartis Pharmaceuticals distributed the single-pill combination of valsartan-hydrochlorothiazide in reminder packaging (RP) for patients receiving this antihypertensive agent from Walmart pharmacies. Only Walmart pharmacies received valsartan-hydrochlorothiazide in RP. Patients' subsequent refills were switched to RP when their prescriptions of valsartan-hydrochlorothiazide without reminder packaging (non-RP) were depleted. The purpose of this study was to assess the impact of this RP on patient adherence to valsartan-hydrochlorothiazide over a continuous 11-month period. We evaluated the medication possession ratio, proportion of days covered, time to refill, and time to discontinuation as primary measures of adherence and persistence in patients who received the repackaged product compared with patients without RP.

Materials and methods
=====================

Databases
---------

Cases of patients receiving the single-pill combination of valsartan-hydrochlorothiazide RP between April 1, 2009 and July 31, 2010 were obtained from the Walmart pharmacy dataset, and controls of patients receiving the single-pill combination of valsartan-hydrochlorothiazide without RP was obtained from the SourceLx (Wolters Kluwer) database. In October 2009, Walmart pharmacies began receiving the valsartan-hydrochlorothiazide in RP. Patients' subsequent refills were switched to RP when their non-RP prescriptions of valsartan-hydrochlorothiazide were depleted. The Walmart pharmacy dataset contained information from over 4000 Walmart and Sam's Club pharmacies throughout the US. The Wolters Kluwer database comprised 30% of the prescription claims filled in the US and accounted for approximately 160 million patient lives. Data elements include demographic variables (age, gender, and geographic region) and essential prescription information for all antihypertensive and nonantihypertensive medications filled during the study period (date of fill, days supply, National Drug Code number, and fill dates of all prescriptions).

Because all pertinent patient information in the databases were encrypted and deidentified, and no patient contact was involved, no informed consent or approval by an institutional review board was required or sought (the data source was fully compliant with the Health Insurance Portability and Accountability).

Sample selection
----------------

Patients were identified in both cohorts and were eligible for analysis if they met all of the following criteria: ≥18 years of age at index prescription date; had at least two hypertension prescriptions in the pre-index and post-index period; did not switch from RP to non-RP; did not receive prescriptions of antihypertensive therapy where days supply was ≥90 days; and did not switch pharmacies. Within the Wolters Kluwer dataset, prescriptions filled by pharmacies outside of the initial pharmacy chain could be included in the patient fill history. Wolters Kluwer identified all patients filling in a pharmacy other than their initial pharmacy affiliations. These patients were subsequently removed to ensure a more valid comparison with Walmart patients. The Walmart database only includes prescriptions filled at Walmart-affiliated pharmacies. Not imposing this criterion would have caused adherence to appear higher for patients in the Wolters Kluwer cohort.

The date of the first antihypertensive therapy (valsartan-hydrochlorothiazide combination) received during that period was assigned as the index date ([Figure 1](#f1-ppa-6-499){ref-type="fig"}). From that date, 6 months of pre-index data and up to 11 months post-index data were collected for all eligible patients. Patients had to have continuous plan enrollment for the 6-month period prior to and at least 11 months following the index date to ensure complete baseline and follow-up information on all patients in the study ([Figure 1](#f1-ppa-6-499){ref-type="fig"}).

Study groups
------------

RP patients were propensity score-matched to non-RP patients (1:1) on pre-index valsartan-hydrochlorothiazide adherence, the month of their first valsartan-hydrochlorothiazide prescription after October 2009 (the index date), age, gender, number of unique antihypertensive drug classes, number of unique nonantihypertensive prescription classes filled, geographic region, and their chronic disease score (determined by pharmacy claims). Matching was done using the technique of nearest available match on pre-index adherence (±0.5 units) and estimated propensity score (±0.001 units). As demonstrated in [Table 1](#t1-ppa-6-499){ref-type="table"}, the matching process was successful in creating cohorts with similar demographic and clinical characteristics, with standardized difference values after the match being \<10% for all baseline characteristics.

Description of RP
-----------------

The RP was a blister-packaged container of 30 nonscored valsartan-hydrochlorothiazide combination tablets. As shown in [Figure 2](#f2-ppa-6-499){ref-type="fig"}, the RP calendar-style container was developed with three rows of 10 tablets. Clear labeling information (days supplied, brand/generic name, storage information, instructions for use) was found on the front of the RP container. A full color photograph of the valsartan-hydrochlorothiazide tablet was provided on the cover for easy recognition. Instructions on how to open the RP were printed on the outside container cover. A reminder to reorder was found inside the blister card insert to prompt the reordering of refills by patients at the end of each monthly regimen.

Measures
--------

To determine if RP improved adherence and persistence, the following outcomes of interest were assessed: medication possession ratio, time to refill, proportion of days covered, and time to discontinuation. Because this dataset did not contain medical claims information, measures could not be adjusted for hospitalizations. Such factors were assumed to be equivalent across cohorts.

### Medication possession ratio

Medication possession ratio evaluated both medication skipping and stopping between the first and last observed prescription. This measure is more appropriate when there is an increased likelihood that all prescriptions filled for a medication may not exist in a database, or that discontinuation of a prescription is likely because of a physician order. It was calculated as the ratio of days supply of medication to total number of days between the first and last prescriptions. Patients who consistently refilled early and may have had medication possession ratio values \>100% were deemed to have a medication possession ratio value of 100%.

### Proportion of days covered

Proportion of days covered was a composite measure that evaluated both medication skipping and stopping. It was calculated as the ratio of days supply of medication to total number of days in the follow-up period (11 months). Patients who consistently refilled early and may have had proportion of days covered values \>100% were deemed to have a proportion of days covered value of 100%.

### Time to discontinuation

Patient length of therapy or time to discontinuation measured continuous treatment without prolonged gaps in therapy. Patients were deemed to have discontinued therapy when more than 30 days had elapsed without a prescription refill. A patient's length of therapy was calculated from the index date to the expected end date of the last prescription prior to discontinuing therapy.

### Time to refill

Based on the above methods, the time between successive refills of relevant medications was calculated. The mean time to refill was calculated using all prescriptions within the defined analysis period. Adherence and persistence outcomes were initially assessed over the 6-month post-index period, with a subsequent 11-month validation analysis completed to assess stability of adherence and persistence over a longer duration of time. Given the similarity of the results, only the 11-month data are presented within the context of this paper.

Statistical analysis
--------------------

Before-match baseline characteristics were compared using *t*-tests for continuous variables and Chi-square tests for categorical variables. After-match continuous variables were compared using paired *t*-tests, and categorical variables were compared using McNemar's test, with an a priori level of significance of alpha = 0.05. Differences in time to discontinuation were assessed utilizing Cox proportional hazards model. All analyses were performed using SAS version 9.2 (SAS, Cary, NC).

Results
=======

A total of 9266 matched patients were included in the analysis (4633 in both RP and non-RP groups). Following cohort matching, the baseline characteristics for the comparison groups were well balanced, and after-match standardized differences were \<10% for all baseline characteristics ([Table 1](#t1-ppa-6-499){ref-type="table"}). The mean age (standard deviation) of the sample was 62 years and was predominantly female in both cohorts (62%).

With similar baseline adherence (medication possession ratio 82%), the post-index adherence was significantly higher in the RP cohort (patients who switched from valsartan-hydrochlorothiazide combination therapy without RP to valsartan-hydrochlorothiazide combination therapy with RP) compared with the non-RP cohort (valsartan-hydrochlorothiazide combination patients who did not switch to RP, medication possession ratio 80% for RP cohort versus 73% for the non-RP cohort; proportion of days covered 76% for RP group versus 63% for non-RP group; both *P* \< 0.001, [Table 2](#t2-ppa-6-499){ref-type="table"}).

The refill timing was 10 days for RP patients versus 16 days for non-RP patients (*P* \< 0.001). Similar trends were observed with respect to time to discontinuation (196 days for RP patients versus 174 days for non-RP patients; *P* \< 0.001), with a higher proportion of patients in the RP cohort remaining on therapy compared with the non-RP cohort (34% versus 30%; *P* \< 0.001 respectively, [Figure 3](#f3-ppa-6-499){ref-type="fig"}). Survival analysis indicated that patients in the RP cohort were 17% less likely to discontinue therapy compared with patients in the non-RP cohort (hazards ratio 0.833; confidence interval 0.79--0.875). When evaluating adherence rates after stratifying by pre-index medication possession ratio categories, the medication possession ratio was higher in the post-index period for both cohorts when the pre-index medication possession ratio was between 0% and 59%. Compared with non-RP patients, the RP patients with a pre-index medication possession ratio between 20% and 79% showed a greater improvement in pre-index to postindex medication possession ratio values ([Table 3](#t3-ppa-6-499){ref-type="table"}). In the highest medication possession ratio category (80%--100%), the reduction in mean pre-index and post-index medication possession ratio values was less in the RP cohort (10.55%) than in non-RP cohort (16.5%; *P* = 0.0001 for pre-and post differences between cohorts, [Table 3](#t3-ppa-6-499){ref-type="table"}).

Discussion
==========

Patient adherence is a principal concern in comprehensive patient care. Nonadherence is a primary reason why full treatment benefits are not realized.[@b8-ppa-6-499] In addition to the clinical ramifications, it is estimated that the overall cost of medication nonadherence ranges from \$100 billion to \$300 billion per year, further quantifying the problem of nonadherence.[@b22-ppa-6-499] Increasing patient adherence patterns will have a substantial impact on medical treatment outcomes.[@b23-ppa-6-499] Our analysis demonstrates the potential impact of adherence-aiding strategies, such as RP and reminder calendar packaging, on patient adherence. This large, propensity-matched sample demonstrated that patients on an antihypertensive regimen (an angiotensin receptor blocker-hydrochlorothiazide combination) showed consistent improvement in adherence and persistence through the use of RP. Our research represents one of the first real-world studies to evaluate the role of RP on adherence and persistence in single-pill combination antihypertensive therapy. This research could lead to further advances in antihypertensive packaging, smart packaging, and patient reminder systems. Enhancements in dosing instructions or an increased amount of space allocated on the outside of packaging may also accompany RP efforts to promote greater patient education and improve adherence.

Previous research comparing calendar blister packaging with traditional prescription bottles in patients with cardiovascular disease and hypertension has shown similar medication adherence benefits.[@b10-ppa-6-499],[@b19-ppa-6-499],[@b20-ppa-6-499],[@b24-ppa-6-499],[@b25-ppa-6-499] A systematic review of 10 randomized controlled trials showed that calendar RP combined with education and other reminder strategies may lead to improved adherence.[@b24-ppa-6-499] A recent meta-analysis assessing the effect of RP on blood pressure measurements found that RP significantly decreased diastolic blood pressure (mean difference 5.89 mmHg; 95% confidence interval −6.70, −5.09; *P* \< 0.00001). This study also found the presence of a RP aid was preferred by patients with low literacy levels.[@b26-ppa-6-499] However, high-quality studies of adequate size and duration in the real world are still needed to assess the clinical effectiveness of RP interventions in therapy further. The use of technology in adherence, such as phone call reminders, electronic medication reconciliation, text messages, interactive voice responses, and programmed electronic audiovisual reminders, is evolving and requires further assessment. These technologic advances may be beneficial when combined with RP and be more practical adherence-modifying strategies.[@b27-ppa-6-499],[@b28-ppa-6-499]

The clinical effectiveness of calendar RP may be greatest in patients who are most likely to forget, such as the elderly. Supporting this premise are studies showing that medication packaging improved adherence and treatment outcomes in older ambulatory patients and improved the rate of successful self-medication.[@b19-ppa-6-499],[@b29-ppa-6-499] Elderly patients (≥81 years) receiving daily-dose blister packaging (pill calendar) refilled their prescriptions more often (*P* = 0.01), had higher medication possession ratios (*P* = 0.04), and lower diastolic blood pressure (*P* = 0.01) than patients who used traditional bottles.[@b19-ppa-6-499] Additionally, blister packaging and RP may ease the difficulty of accessing medication, as shown in a study which reported that 10% of patients using blister packaging were unable to access their medication, compared with 14% of patients using a screwcap bottle, and 32% of patients using a bottle with a snap lid.[@b30-ppa-6-499] RP strategies that seek to assist elderly patients in managing various types of prescription bottles and to prevent potential adherence barriers could widely improve adherence and corresponding clinical outcomes.

Although RP strategies may achieve improvement in adherence rates and clinically relevant outcomes, there are limited data on the cost-effectiveness of RP in general practice or with combination antihypertensive therapies such as valsartan-hydrochlorothiazide. Skaer et al found that use of a calendar pill organizer for hypertension achieved a \$13.55 decrease in adjusted mean annual total health care costs per patient, which implies the potential for cost savings. [@b31-ppa-6-499] A review of relative cost-effectiveness and adherence interventions found that, on average, the cost of customized medication unit-of-use packaging for 6 months was \$24.76 per patient and resulted in a relative improvement in adherence of 1.17--1.20 over the control group.[@b32-ppa-6-499],[@b33-ppa-6-499] In addition, increased adherence resulted in longer-term savings in the overall costs of treating cardiovascular disease and related conditions.[@b32-ppa-6-499],[@b33-ppa-6-499] An evaluation of the impact of medication adherence on health care utilization and costs for hypertension and other cardiovascular disease-related conditions suggests that increased drug utilization is driven by improved adherence.[@b34-ppa-6-499] Sokol et al found that all-cause hospitalization rates were lowest for patients with hypertension who had the highest level of medication adherence. The average return on investment for a 20% increase in drug utilization was 4.0.[@b34-ppa-6-499]

Although the evidence highlighting the value of RP in our study was very positive, there are limitations that should be considered. As with any retrospective study, selection bias may confound the relationship between treatment and the outcomes of interest.[@b35-ppa-6-499] To minimize this bias, propensity score matching was used, controlling for a host of demographic and comorbidity measures, as well as baseline adherence. However, due to the nonrandomized nature of the study, propensity matching may not be able to balance unmeasured confounders. Additionally, the unavailability of medical data precluded the evaluation of comorbidities, disease severity, specific disease diagnoses, and hospitalizations.

Even with the aforementioned limitations, few studies have assessed the impact of RP on medications used to treat chronic conditions. Our study demonstrates that RP in the subgroup of patients on single-pill combination antihypertensive therapy has a tremendously positive impact. Although intentional nonadherence is a primary factor in patient failure to achieve treatment outcomes, efforts can be made to address unintentional patient compliance barriers. Unintentional barriers to compliance continue to affect treatment paradigms and often go unnoticed or are rarely addressed. Forgetting to take a medication is a common adherence issue in elderly patients and is attributed to such factors as using more than one pharmacy, seeing multiple physicians, confusion regarding the treatment regimen, mislabeling of containers, and inability to open childproof containers.[@b18-ppa-6-499] RP is a tool to improve unintentional barriers associated with patient compliance in all patient groups, and especially in elderly populations. The ease of use of reminder daily-dose blister packaging offers multiple patient benefits compared with traditional bottles and loose tablets. The use of this patient-friendly packaging has significant effects on adherence and persistence.

Conclusion
==========

This real-world assessment of differences in adherence and persistence in treated hypertensive patients who switched to RP therapy compared with those who did not indicates that patients receiving RP were more adherent and persistent in their treatment regimens. Improvements in adherence were assessed by increases in medication possession ratio and proportion of days covered. An increase in persistence was measured by shorter gaps between successive refills in the RP cohort over an 11-month period. These findings were also consistent when the analysis was stratified by baseline levels of adherence. This matched patient analysis successfully demonstrates the positive effect of RP on antihypertensive therapy adherence and persistence rates.
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**Notes:** The index date for first VAL-HCT-RP was defined as the first fill of Diovan^®^ HCT-RP, which occurred after October 28, 2009 (the date the packaging was released into the marketplace). The period of time that patients were identified for study inclusion based on their first fill of VAL-HCT-RP was considered as the enrollment period, which ranged from October 28, 2009 through January 31, 2010, allowing for patients to be followed for 6 months pre-index and post-index Diovan HCT-RP prescription.\
**Abbreviations:** RP, reminder packaging; non-RP, without reminder packaging; VAL-HCT, valsartan-hydrochlorothiazide combination.](ppa-6-499f1){#f1-ppa-6-499}

![Reminder packaging dispensed to patients.](ppa-6-499f2){#f2-ppa-6-499}

![Time-to-event (treatment discontinuation) analysis.](ppa-6-499f3){#f3-ppa-6-499}

###### 

Baseline characteristics: after match

  Characteristics                                                                                                            RP (n = 4633)   non-RP (n = 4633)   *P* value[a](#tfn2-ppa-6-499){ref-type="table-fn"}   Standardized difference            
  -------------------------------------------------------------------------------------------------------------------------- --------------- ------------------- ---------------------------------------------------- ------------------------- -------- ------
  Demographic characteristics                                                                                                                                                                                                                            
   Age (mean, SD)                                                                                                            62.07           12.60               62.02                                                12.16                     0.8262   0.45
   Female (n, %)                                                                                                             2900            62.59               2889                                                 62.36                     0.8250   0.49
   Region (n, %)                                                                                                                                                                                                                                         
    Midwest                                                                                                                  849             18.33               901                                                  19.45                              2.87
    Northeast                                                                                                                675             14.57               677                                                  14.61                     0.6556   0.12
    South                                                                                                                    2711            58.52               2656                                                 57.33                              2.40
    West                                                                                                                     398             8.59                399                                                  8.61                               0.08
  Adherence in pre-index period (mean, SD)                                                                                                                                                                                                               
   MPR                                                                                                                       82.43           18.63               82.57                                                19.39                     0.6910   0.77
   Refill timing (days)                                                                                                      8.77            14.61               8.84                                                 13.55                     0.7971   0.51
  Prescription counts in pre-index period (mean, SD)                                                                                                                                                                                                     
   Unique HTN Rx classes (n)                                                                                                 0.62            0.79                0.62                                                 0.79                      0.8183   0.44
   Unique HTN Rxs (n)                                                                                                        0.64            0.82                0.63                                                 0.82                      0.7718   0.55
   Unique non-HTN Rx classes (n)                                                                                             4.41            3.62                4.47                                                 3.75                      0.4224   1.55
   Unique non-HTN Rxs (n)                                                                                                    4.61            3.89                4.68                                                 4.05                      0.3072   1.97
  Comorbidity in pre-index period                                                                                                                                                                                                                        
   Cardiovascular CDS I[b](#tfn3-ppa-6-499){ref-type="table-fn"},[c](#tfn4-ppa-6-499){ref-type="table-fn"} (mean, SD)        1.38            1.69                1.37                                                 1.67                      0.8649   0.33
   Non-cardiovascular CDS II[b](#tfn3-ppa-6-499){ref-type="table-fn"},[d](#tfn5-ppa-6-499){ref-type="table-fn"} (mean, SD)   2.24            2.25                2.27                                                 2.30                      0.5337   1.25
   Other diseases (n, %)                                                                                                                                                                                                                                 
    Renal disease                                                                                                            2               0.04                3                                                    0.06                      1.0000   0.93
    End-stage renal disease                                                                                                  1               0.02                1                                                    0.02                      1.0000   0.00
    Cystic fibrosis                                                                                                          2               0.04                1                                                    0.02                      1.0000   1.20
    Liver failure                                                                                                            7               0.15                9                                                    0.19                      0.8036   1.04
    Transplantation                                                                                                          0               0.00                1                                                    0.02                      --       --
    Thyroid disorders                                                                                                        587             12.67               592                                                  12.78                     0.8987   0.32
    Pain and inflammation                                                                                                    837             18.07               828                                                  17.87                     0.8180   0.51
    Pain                                                                                                                     1020            22.02               1009                                                 21.78                     0.7957   0.57
    Depression                                                                                                               928             20.03               911                                                  19.66                     0.6730   0.92
    Psychotic illness                                                                                                        78              1.68                84                                                   1.81                      0.6771   0.99
    Bipolar disorder                                                                                                         4               0.09                3                                                    0.06                      1.0000   0.79
    Human immunodeficiency virus                                                                                             114             2.46                102                                                  2.20                      0.4368   1.72
    Anxiety and tension                                                                                                      613             13.23               565                                                  12.20                     0.1094   3.11

**Notes:**

*t*-test for continuous variables and Chi-square test for categorical variables;

CDS is calculated by assigning a weight (score) to each drug class to correspond to disease complexity and severity. It is an aggregate of the assigned weights based on medication use, but not on frequency of use;

CDS I is derived based on hypertensive (excluding valsartan-hydrochlorothiazide claims) and cardiac medications, by assigning scores suggested by Von Korff et al.[@b21-ppa-6-499] Range (0--7);

CDS II is derived based on medications of epilepsy, tuberculosis, rheumatologic conditions, hyperlipidemia, malignancies, Parkinson's disease, diabetes, glaucoma, ulcer, respiratory illness, gout, acne, migraines, Crohn's disease, and coronary disease by assigning scores suggested by Von Kroff et al.[@b21-ppa-6-499] Range (0--27) Standardized difference = 100 \* (x1 − x2)/√ {(s12 + s22)/2}, where x1 = mean of group 1, x2 = mean of group 2, s1 = standard deviation of group 1, and s2 = standard deviation of group 2.

**Abbreviations:** CDS, chronic disease score; ESRD, end-stage renal disease; HIV, human immunodeficiency virus; HTN, hypertension; MPR, medication possession ratio; RP, reminder packaging; Rx, prescription; SD, standard deviation; non-RP, without reminder packaging.

###### 

Adherence and persistency outcomes

  Outcome                           RP (n = 4633)   non-RP (n = 4633)   *P* value[a](#tfn8-ppa-6-499){ref-type="table-fn"}             
  --------------------------------- --------------- ------------------- ---------------------------------------------------- --------- ----------
  Adherence (mean, SD)                                                                                                                 
   MPR                              79.6            (18.7)              73.2                                                 (21.3)    \<0.0001
   PDC                              65.2            (26.2)              62.7                                                 (25.1)    \<0.0001
  Persistence (mean, SD)                                                                                                               
   Time to discontinuation (days)   195.9           (115.8)             174.0                                                (118.6)   \<0.0001
   Refill timing (days)             10.4            (16.5)              15.6                                                 (20.0)    \<0.0001

**Notes:** Refill timing: time between successive refills of valsartan-hydrochlorothiazide.

Paired *t*-test. Matching was based on propensity scores.

**Abbreviations:** MPR, medication possession ratio; PDC, proportion of days covered; RP, reminder packaging; SD, standard deviation; non-RP, without reminder packaging.

###### 

Outcomes stratified by pre-index medication possession ratio categories

  Pre-period MPR categories (%)   RP     non-RP   *P* value[a](#tfn12-ppa-6-499){ref-type="table-fn"}                                                                                                                                                      
  ------------------------------- ------ -------- ----------------------------------------------------- -------------------------------------------------- --------- ------ ------- --------- -------------------------------------------------- --------- --------
  MPR                                                                                                                                                                                                                                                      
   0--19                          3      10.89    (7.58)                                                58.73                                              (26.88)   2      4.83    (0.16)    41.21                                              (8.36)    0.6105
   20--39                         144    30.76    (5.52)                                                62.24[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (21.07)   153    34.29   (4.06)    57.32[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (19.66)   0.0008
   40--59                         466    50.20    (5.18)                                                66.31[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (20.66)   584    50.28   (5.29)    60.84[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (20.46)   0.0001
   60--79                         1098   70.92    (5.32)                                                76.18[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (18.93)   905    70.23   (5.83)    66.12[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (20.15)   0.0001
   80--100                        2922   94.51    (5.98)                                                83.95[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (16.18)   2989   95.15   (5.90)    78.65[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (19.74)   0.0001
  Refill timing (days)                                                                                                                                                                                                                                     
   0--19                          3      93.67    (29.57)                                               27.37                                              (21.82)   2      88.00   (16.97)   43.33                                              (15.08)   0.6118
   20--39                         144    67.76    (19.56)                                               24.52[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (24.52)   153    56.25   (11.84)   0.12[\*](#tfn11-ppa-6-499){ref-type="table-fn"}    (23.10)   0.0001
   40--59                         466    29.33    (6.56)                                                20.40[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (21.57)   584    29.08   (6.69)    25.17[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (22.75)   0.0004
   60--79                         1098   11.69    (3.40)                                                12.48                                              (17.42)   905    12.32   (4.22)    20.31[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (20.71)   0.0001
   80--100                        2922   1.40     (2.00)                                                7.35[\*](#tfn11-ppa-6-499){ref-type="table-fn"}    (13.36)   2989   1.36    (2.06)    11.61[\*](#tfn11-ppa-6-499){ref-type="table-fn"}   (17.73)   0.0001

**Notes:**

*P* \< 0.05 versus pre-period values (paired *t*-test).

Statistical test: unpaired *t*-test for pre-post difference scores.

**Abbreviations:** MPR, medication possession ratio; non-RP, without reminder packaging; RP, reminder packaging; SD, standard deviation.
